Coya Therapeutics, Inc. Common Stock (COYA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $4.89 (+2.73%), Market cap $0.10B, 52-week low–high $3.78 ~ $7.36.
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer's disease (AD), and Parkinson's disease. In addition, its pre-clin
Financial statements, price targets, institutional (13F) holdings and related news for Coya Therapeutics, Inc. Common Stock are updated in real time on BlackAll Trade.
Coya Therapeutics, Inc. Common Stock trades at $4.89 (+2.73%). Real-time quotes and charts are available on BlackAll Trade.
Coya Therapeutics, Inc. Common Stock has a market cap of about $0.10B.
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeli